Journal Guide

Ethics and Education is a new international, peer-reviewed journal which aims to stimulate discussion and debate around the ethical dimensions of education.The journal addresses issues in both formal and informal education and upbringing, and includes within its scope relevant aspects of applied ethics, including:BioethicsMedical ethicsManagement ethicsSex educationEthics of therapy and counsellingProfessional ethicsEthics and Education welcomes all traditions and forms of ethical enquiry, from a wide range of philosophical and religious perspectives. As well as appealing to those with a direct interest in ethics and education, the journal will also be of interest to philosophers, educationalists, policy-makers.Peer Review Policy:All research articles in this journal have undergone rigorous peer review, based on initial editor screening and anonymized refereeing by at least two anonymous referees.Disclaimer for Scientific, Technical and Social Science publications:Taylor & Francis makes every effort to ensure the accuracy of all the information (the Content ) contained in its publications. However, Taylor & Francis and its agents and licensors make no representations or warranties whatsoever as to the accuracy, completeness or suitability for any purpose of the Content and disclaim all such representations and warranties whether express or implied to the maximum extent permitted by law. Any views expressed in this publication are the views of the authors and are not the views of Taylor & Francis.

Ethnopolitics is an authoritative peer-reviewed journal which provides a forum for serious debate and exchange on one of the phenomena that had a decisive impact during the last decades of the 20th century and continues to be of great importance in the new millennium. The journal gives a voice to established as well as younger researchers and analysts from academic as well as practitioner backgrounds. We publish original articles of the highest quality in the field of ethnopolitics: our section 'Briefings and Analysis' in particular offers such articles with a specific focus on current events and developments. The 'Symposium' section provides a forum for engagement and discussion on issues that are of fundamental importance for theoretical and policy debates in our areas of interest. Ethnopolitics maintains a fair balance between theoretical analyses and case studies both of comparative as well as singular nature, covering all geographic areas. The major focus is on the analysis, management, settlement, and prevention of ethnic conflicts, on minority rights, group identity, the intersection of identity group formations and politics, on minority and majority nationalisms in the context of transitions to democracy, and on the security and stability of states and regions as they are affected by any of the above issues. Particular attention is also devoted to the growing importance of the international dimension of ethnopolitics, including diplomatic and military interventions, and the increasing impact of globalisation on ethnic identities and their political expressions.Ethnopolitics is a journal of the Specialist Group on Ethnopolitics and the Association for the Study of Nationalities. A particular feature of Ethnopolitics is the publication of special issues. Focusing on one specific topic and examining it in a comprehensive manner, special issues of Ethnopolitics are edited by scholars and practitioners with particular expertise in the subject matter. Contributions, which are normally invited by the editors, undergo the same rigorous review procedures as articles published in 'regular' issues of the journal. Special issues will be published in parallel also as free-standing books, thus increasing the audience beyond individual and institutional subscribers to Ethnopolitics.Peer ReviewAll research articles in this journal have undergone rigorous peer review, based on initial editor screening and anonymized refereeing by at least two anonymous referees. Disclaimer The Editors of Ethnopolitics and Taylor & Francis make every effort to ensure the accuracy of all the information (the 8220;Content8221;) contained in its publications. However, the Editors of Ethnopolitics and Taylor & Francis and its agents and licensors make no representations or warranties whatsoever as to the accuracy, completeness or suitability for any purpose of the Content and disclaim all such representations and warranties whether express or implied to the maximum extent permitted by law. Any views expressed in this publication are the views of the authors and are not necessarily the views of the Editors of Ethnopolitics or Taylor & Francis.

The  European Competition Journal publishes outstanding scholarly articles relating to European competition law and economics. Its mission is to help foster learning and debate about how European competition law and policy can continue to develop in an economically rational way. Articles published in the Journal are subject to rigorous peer review by leading experts from around Europe. Topics include:

• Vertical and Conglomerate Mergers
• Enlargement of the Union - the ramifications for Competition Policy
• Unilateral and Coordinated Effects in Merger Control
• Modernisation of European Competition law
• Cartels and Leniency

EJES presents work of the highest quality in English literature, linguistics and cultural studies from the multidisciplinary and multicultural perspective that characterises the study of English in Europe. The aim of the journal is to publish substantial scholarly and critical interventions in a fast-developing field and thereby itself to influence the agenda in its disciplines. A research journal, written by and for specialists from all parts of the disciplinary spectrum of English Studies in Europe and beyond, EJES is also addressed to academics interested in the dialogical and plurivocal development of their subject and are interested in innovative work outside their own area of expertise. To this end, it also offers non-specialists examples of recent approaches and new ways of conceiving and engaging the field of English studies. The journal places a high premium on readability, discussion of controversial issues, and the inclusion of a wide range of disciplinary, cultural and theoretical perspectives. EJES appears three times a year. Individual issues are devoted to specific themes, proposed by guest editors, and designed to attract cutting-edge research from across and between the disciplines that make up English Studies in Europe and beyond. A substantial book review section keeps readers informed about new publications in the field, particularly where these challenge existing assumptions or offer to make a difference to the practice of the discipline. 'The cause is Europe . . . The cause is also English Studies in the broadest sense of that term . . . Moreover, the cause is debate.' (Editorial, EJES 1.1) Disclaimer Taylor & Francis makes every effort to ensure the accuracy of all the information (the 'Content') contained in its publications. However, Taylor & Francis and its agents and licensors make no representations or warranties whatsoever as to the accuracy, completeness or suitability for any purpose of the Content and disclaim all such representations and warranties whether express or implied to the maximum extent permitted by law. Any views expressed in this publication are the views of the authors and are not the views of Taylor & Francis.

Evidence & Policy is the first peer-reviewed journal dedicated to comprehensive and critical assessment of the relationship between research evidence and the concerns of policy makers and practitioners, as well as researchers.

Expert Opinion on Biological Therapy ranks #42 of 160 in the Biotechnology & Applied Microbiology category and #30 of 106 in the Medicine, Research & Experimental category in the 2009 ISI Journal Citation Reports.Expert Opinion on Biological Therapy (ISSN 1471-2598 [print], 1744-7682 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on all aspects of biological therapy, providing expert opinion on the scope for future development.The Editors welcome: * Reviews covering gene therapy and gene transfer technologies; therapeutic peptides and proteins; vaccines and antibodies; cell- and tissue-based therapies * Drug Evaluations reviewing the clinical data on a particular biological agent * Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practiceThe audience consists of scientists and managers in the healthcare and biopharmaceutical industry and others closely involved in the development of biological therapy for the treatment of human disease.

Expert Opinion on Drug Delivery ranks #32 of 249 in the in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Delivery (ISSN 1742-5247 [print], 1744-7593 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders * Technology Evaluations reviewing a particular drug delivery technologyThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents.

Expert Opinion on Drug Metabolism & Toxicology ranks #66 of 249 in the Pharmacology & Pharmacy category and #112 of 286 in the Biochemistry and Molecular Biology category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.The Editors welcome: * Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data * Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drugThe audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.

Expert Opinion on Drug Safety ranks #100 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development. * Reviews covering occurrence, management and prevention of drug-associated adverse events; risk-benefit analyses of individual drugs and drug classes; safety in 'at-risk' patient populations; comparative tolerability studies; pharmacovigilance and pharmacoepidemiological studies * Drug Safety Evaluations reviewing the safety data on a particular drug * Original Research papers reporting the results of post-marketing surveillance and other safety studies looking at specific drugs, populations and outcomes; methods for the detection and evaluation of drug-associated adverse eventsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in monitoring drug safety.Read More: http://informahealthcare.com/page/Description?journalCode=eds.

Expert Opinion on Emerging Drugs ranks #69 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.Each review article is structured to include: * Concise background to the subject matter * Assessment of medical need for alternative or novel therapies * Assessment of the market and anticipated changes over time * Summary of current research goals * Outline of the scientific rationale for the approach(es) considered< * Analysis of the competitive environment * Discussion of potential development issues * The author’s expert opinion on the potential impact emerging therapies will have on the current management of specific diseasesThe audience consists of pharmaceutical and academic scientists, research planners, pharmaceutical product mangers, clinical opinion leaders and healthcare planners.

Expert Opinion on Investigational Drugs ranks #35 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. * Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trialsThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.

Expert Opinion on Pharmacotherapy ranks #120 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Pharmacotherapy (ISSN 1465-6566 [print], 1744-7666 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.The Editors welcome: * Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies * Drug Evaluations reviewing the clinical and pharmacological data on a particular drug * Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practiceThe audience consists of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.

Expert Opinion on Therapeutic Patents ranks #3 of 13 in the Medicine, Legal category and #118 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. * Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area * Patent Evaluations examining the aims and chemical and biological claims of individual patents * Perspectives on issues relating to intellectual propertyThe audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D.

Expert Opinion on Therapeutic Targets ranks #53 of 249 in the Pharmacology & Pharmacy category in the 2010 ISI Journal Citation Reports.Expert Opinion on Therapeutic Targets (ISSN 1472-8222 [print], 1744-7631 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on recently identified novel molecular drug targets, providing expert opinion on the scope for future development and impact on drug discovery.The Editors welcome: * Reviews covering novel disease targets at the molecular level and their implications on future drug development * Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugsThe audience consists of scientists, managers and decision makers in the pharmaceutical industry, and others closely involved in R&D.Read More: http://informahealthcare.com/page/Description?journalCode=ett.

Expert Review of Anti-infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.The Expert Review format is unique. Each review provides a complete overview of current thinking in a key area of anti-infective research or clinical practice. This comprehensive coverage is augmented by:Expert Commentary- a personal view on the most effective or promising strategiesFive-year view - a clear perspective of future prospects within a realistic timescaleKey issues - an executive summary cutting to the author's most critical points.

Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.

Through recent research advances we are increasingly able to understand and address immune-mediated diseases. Biotechnology is yielding success in areas with a strong immunologic component, such as allergic asthma, rheumatoid arthritis, inflammatory bowel disease, psoriasis and multiple sclerosis. Nevertheless, the burden of immune-mediated diseases is still enormous, with direct and indirect costs associated with such conditions believed to exceed $100 billion in the USA alone.Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology.